The EVP & GC of Exelixis is Exercising Options

By Carrie Williams

Yesterday, the EVP & GC of Exelixis, Jeffrey Hessekiel, exercised options of Exelixis for $42.5K.

Following this transaction Jeffrey Hessekiel’s holding in the company was increased by 7.93% to a total of $7.08 million. This is Hessekiel’s first Buy trade following 3 Sell transactions.

See today’s analyst top recommended stocks >>

Based on Exelixis’ latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $120 million and quarterly net profit of $38.49 million. In comparison, last year the company earned revenue of $80.89 million and had a net profit of $16.64 million. The company has a one-year high of $32.50 and a one-year low of $18.03. EXEL’s market cap is $6.32B and the company has a P/E ratio of 42.49.

Based on 5 analyst ratings, the analyst consensus is Strong Buy with an average price target of $35.00, reflecting a -40.5% downside. 11 different firms, including Cowen & Co. and Deutsche Bank, currently also have a Buy rating on the stock. Starting in February 2018, EXEL received 9 Buy ratings in a row.

The insider sentiment on Exelixis has been negative according to 47 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Exelixis, Inc. is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B.